Agenus will present long-term survival data for its BOT+BAL combination in colorectal cancer at the Society for Immunotherapy of Cancer (SITC) 2026 annual meeting, alongside translational research on agenT-797, the company confirmed in an announcement carried by BioSpace.

The disclosure puts two distinct assets in front of the immuno-oncology field at the same congress. The first is the antibody pairing of botensilimab (BOT), an Fc-engineered anti-CTLA-4 antibody, and balstilimab (BAL), a PD-1 inhibitor — a combination Agenus has positioned as a checkpoint backbone for tumors that respond poorly to conventional anti-PD-1 therapy. The second is agenT-797, an invariant natural killer T (iNKT) cell therapy candidate, for which the company will show translational work in colorectal cancer rather than primary clinical outcomes.

For R&D portfolio managers, the structure of the presentation matters as much as its content. Agenus is framing the meeting around durability — the phrase "long-term survival data" signals that the company has follow-up extending beyond initial response reads, the metric payers, regulators and licensing partners weigh most heavily in colorectal cancer. Microsatellite-stable colorectal cancer, the subtype that dominates the disease and has historically resisted checkpoint monotherapy, is the setting where a survival tail, if it holds up, would carry the most commercial and scientific weight. The announcement as distributed does not specify median follow-up duration, patient numbers, or hazard ratios; those details will land with the abstract and poster publications at the congress itself.

The agenT-797 program points in a different strategic direction. Translational data — tumor immune microenvironment profiling, persistence of the engineered cells, biomarker correlates — serves as the evidentiary bridge that determines whether a cell therapy platform advances into later-line or earlier-line trials. Presenting such work at SITC, rather than at a cell-therapy-specific meeting, positions agenT-797 as a combinational partner for Agenus's own checkpoint franchise, an increasingly common portfolio play among mid-cap oncology companies seeking to defend pipeline economics as standalone anti-PD-1 assets lose pricing power.

Agenus enters the meeting under familiar pressure. The Lexington, Massachusetts-based company has pursued partnerships and asset monetization to fund its clinical pipeline, and congress appearances of this kind function as marketing to potential licensees as much as scientific exchange. R&D managers evaluating the data should apply the standard filters: who funded the work (Agenus, in this case, both sponsor and presenter), whether the survival figures come from randomized comparison or single-arm cohorts, and whether the translational agenT-797 findings involve clinically treated patients or preclinical models. The announcement does not distinguish among these, and the difference determines how much weight the results can bear.

The venue choice is deliberate. SITC, the largest meeting dedicated to cancer immunotherapy, draws the translational immuno-oncology community — precisely the reviewers who will scrutinize mechanistic claims for an iNKT cell therapy and durability claims for a CTLA-4/PD-1 pairing. Presenting both programs together lets Agenus argue an integrated biology story: priming and checkpoint release via BOT+BAL, coupled with innate-like cellular effectors via agenT-797.

What to watch when the abstracts drop. The single most consequential number will be the duration of the survival tail in the BOT+BAL colorectal cancer cohort and the denominator behind it — how many patients were treated, in which lines of therapy, and at what dose levels, given botensilimab's dose-dependent immune activity. For agenT-797, the translational dataset should be read for evidence of cell persistence and tumor infiltration in humans, not just peripheral blood markers. Absent randomized controls, both datasets will be hypothesis-generating rather than practice-defining, and partnering discussions — if the data land — will hinge on whether Agenus can show the survival benefit holds as follow-up lengthens.

The full dataset, including abstract numbers, presentation times and authorship, will be available when SITC 2026 releases its scientific program.